News >

Expert Discusses Durvalumab for Urothelial Carcinoma

Shannon Connelly
Published: Tuesday, Jun 20, 2017

Christophe Massard, MD, PhD

Christophe Massard, MD, PhD

The FDA approved the PD-L1 inhibitor durvalumab (Imfinzi) in May 2017 for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

The approval was based on the single-arm phase I/II Study 1108, which included 182 patients with locally advanced or metastatic urothelial carcinoma who experienced disease progression following platinum-containing chemotherapy.

In the study, the objective response rate per blinded independent central review was 17.0% (95% CI, 11.9-23.3). At the data cutoff, the median duration of response was not reached (range, 0.9+ to 19.9+ months).

In an interview with OncLive, Christophe Massard, MD, PhD, medical oncologist, senior consultant of the Drug Development Department and Department of Medical Oncology, and chairman of the Early Drug Development Multidisciplinary Tumor Board, Gustave Roussy Institute, discussed the latest developments with durvalumab in urothelial carcinoma.

OncLive: Please provide some background on durvalumab leading up to its approval.

Massard: Durvalumab is a selective, high-affinity, engineered human IgG1 monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80. An ongoing, multicenter, phase I/II open-label study (NCT1693562) is evaluating the safety and antitumor activity of durvalumab monotherapy in patients with advanced solid tumors, including locally advanced/metastatic urothelial carcinoma. An interim analysis of 61 patients with urothelial carcinoma in this study indicated that durvalumab was well tolerated and associated with antitumor activity, particularly in patients with PD-L1–high disease (≥25% of tumor cells or tumor-infiltrating immune cells express PD-L1), resulting in its breakthrough therapy designation by the FDA.

In [the] phase I/II open label study of locally advanced/metastatic urothelial carcinoma patients [that led to the approval of durvalumab, the treatment] was administered at 10 mg/kg every 2 weeks. Durvalumab showed favorable efficacy and an excellent safety profile in locally advanced/metastatic urothelial carcinoma patients.

What adverse events were seen with durvalumab on the trial?

Grade 3/4 treatment-related adverse events [AEs] occurred in less than 10% of patients. Grade 3/4 immune-mediated adverse events occurred in a minority of patients. Among patients with any-grade treatment-related AEs of special interest, patients received systemic steroids.

What advice do you have for community oncologists regarding serious or immune-related AEs?

Durvalumab, like other immune checkpoint blockers, generates atypical types of tumor responses—pseudoprogression, but also hyperprogression. Moreover, they have a specific toxicity profile that is challenging the historical oncologists’ practices, with the need to learn how to deal with the clinical management of immune-related AEs.

Most immune-related AEs remain mild in intensity but between 5% and 10% of patients treated with anti–PD-1 immune checkpoint blockers will develop severe, sometimes life-threatening grade 3/4 dysimmune toxicities. For example, it was decided at Gustave Roussy to set up a network of oncologists and organ specialists to manage patients with immune-related AEs. This program is led by Aurélien Marabelle, MD, PhD; Stéphane Champiat, MD; and Olivier Lambotte, MD, PhD.

What is the impact of durvalumab’s FDA approval?

[The research] supports the manageable safety and tolerability of durvalumab administered at 10 mg/kg every 2 weeks as monotherapy in patients with solid tumors and confirms its favorable clinical activity in previously treated patients with locally advanced/metastatic urothelial carcinoma for whom prognosis is poor. Durvalumab is clearly a new option for these patients.

Is there potential for durvalumab to replace chemotherapy?

Based on these findings, durvalumab appears to be an attractive alternative to chemotherapy. Further studies, including DANUBE (NCT02516241), BISCAY (NCT02546661), and Study 10 (NCT02261220), are evaluating durvalumab as a monotherapy and in combination with other agents (tremelimumab, AZD4547, olaparib [Lynparza], AZD1775, and vistusertib) in urothelial carcinoma.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x